Expression of adiponectin and its receptors in avian species

Adipose tissue is a dynamic endocrine organ secreting a variety of hormones that affect physiological functions within the central nervous system, cardiovascular system, reproductive, and immune systems. The endocrine role of avian adipose tissue remains enigmatic as many of the classical hormones found in mammalian adipose tissue have not been found in avians. This mini-review summarizes our current knowledge on avian adiponectin, one of the most abundant adipose tissue hormones, and its receptors. We cloned the genes encoding chicken adiponectin and its receptors, AdipoR1 and AdipoR2. Using anti-chicken adiponectin antibody, we found that chicken adipose tissue and plasma predominantly contain a unique polymer of adiponectin with a mass greater than 669kDa, unlike mammalian adiponectin which is found as three distinct oligomers. Mass spectrometric analyses of chicken adiponectin revealed certain post-translational modifications that are likely to favor the unique multimerization of adiponectin in chickens. Unlike adiponectin, the nucleotide sequences of chicken AdipoR1- and AdipoR2 cDNA are highly similar to that of mammalian adiponectin receptors. Both adiponectin and adiponectin receptors are widely expressed in several tissues in the chicken. Herein, we review the unique biochemistry of adiponectin as well as expression of adiponectin and its receptors in the chicken. Future studies should focus on elucidating the role of adiponectin, AdipoR1, and AdipoR2 on metabolism, steroidogenesis, and adipose tissue remodeling during growth and reproduction in birds.

Nampt/visfatin/PBEF affects expression of myogenic regulatory factors and is regulated by interleukin-6 in chicken skeletal muscle cells

Nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF) has been identified as a rate-limiting NAD(+) biosynthetic enzyme and an adipokine found in the circulation. Human and chicken skeletal muscles are reported to have the highest level of Nampt expression among various tissues whose functional significance remains undetermined. Expression of Nampt is regulated by interleukin-6 (IL-6), an essential cytokine for postnatal muscle growth in mammals. The objective of the current study was to characterize expression of Nampt in chicken (Gallus gallus) myogenic cells and to determine the effect of Nampt on expression of IL-6, myogenic transcription factors, and glucose uptake. We also sought to determine the effect of IL-6 on Nampt expression in chicken myogenic cells. Nampt mRNA and protein were identified in both myoblasts and myocytes, although expression did not differ between the two cell types. Treatment with recombinant human Nampt was found to decrease myoD and mrf4 expression but to increase myf5 expression in myocytes, while glucose uptake was unaffected. In response to treatment with recombinant Nampt, IL-6 expression in myocytes was increased at 24h but decreased when treated for 48 or 72 h. Forced over-expression of chicken Nampt cDNA significantly decreased myf5 expression in myoblasts. Treatment of myogenic cells with lower levels (1 ng.mL(-1)) of recombinant IL-6 increased Nampt expression, whereas a higher IL-6 concentration (100 ng.mL(-1)) decreased Nampt mRNA abundance. Collectively, these results demonstrate that Nampt, regulated in part by IL-6, alters the expression of key myogenic transcription factors and thereby may influence postnatal myogenesis.

Unique profile of chicken adiponectin, a predominantly heavy molecular weight multimer, and relationship to visceral adiposity

Adiponectin, a 30-kDa adipokine hormone, circulates as heavy, medium, and light molecular weight isoforms in mammals. Plasma heavy molecular weight (HMW) adiponectin isoform levels are inversely correlated with the incidence of type 2 diabetes in humans. The objectives of the present study were to characterize adiponectin protein and quantify plasma adiponectin levels in chickens, which are naturally hyperglycemic relative to mammals. Using gel filtration column chromatography and Western blot analysis under nonreducing and non-heat-denaturing native conditions, adiponectin in chicken plasma, and adipose tissue is predominantly a multimeric HMW isoform that is larger than 669 kDa mass. Under reducing conditions and heating to 70-100 C, however, a majority of the multimeric adiponectin in chicken plasma and adipose tissue was reduced to oligomeric and/or monomeric forms. Immunoprecipitation and elution under neutral pH preserved the HMW adiponectin multimer, whereas brief exposure to acidic pH led to dissociation of HMW multimer into multiple oligomers. Mass spectrometric analysis of chicken adiponectin revealed the presence of hydroxyproline and differential glycosylation of hydroxylysine residues in the collagenous domain. An enzyme immunoassay was developed and validated for quantifying plasma adiponectin in chickens. Plasma adiponectin levels were found to be significantly lower in 8- compared with 4-wk-old male chickens and inversely related to abdominal fat pad mass. Collectively, our results provide novel evidence that adiponectin in chicken plasma and tissues is predominantly a HMW multimer, suggesting the presence of unique multimerization and stabilization mechanisms in the chicken that favors preponderance of HMW adiponectin over other oligomers.

Regulation of JAK2 protein expression by chronic, pulsatile GH administration in vivo: a possible mechanism for ligand enhancement of signal transduction

Growth hormone (GH) is a key factor controlling postnatal growth and development. Despite growth-promoting effects in mammals, GH is not associated with muscle growth in the chicken. Janus kinase 2 (JAK2) has been identified as the first intracellular step in GH receptor (GHR) signaling in many species, however, there is limited knowledge regarding the GH signaling pathway in the chicken. In this study, GH-responsive, JAK2 immunoreactive proteins were first assessed in an avian hepatoma cell line (LMH). Tyrosine phosphorylation of a 120-122 kDa JAK2 immunoreactive protein was GH dose-dependent. In addition to in vitro studies, the timecourse of JAK2 activation in liver and skeletal muscle (Pectoralis superficialis) in response to a single intravenous (i.v.) injection of chicken GH (cGH), and the effect of chronic exposure to GH in a physiologically relevant pattern on JAK2 protein expression and tyrosine phosphorylation in vivo were assessed. At a dose of GH that was previously demonstrated to elicit a maximal metabolic response (6.25 microg/kg BW), maximum tyrosine phosphorylation of JAK2 appeared at 10 min post-GH administration in the pectoralis muscle, but was not detectable in liver. To assess whether chronic enhancement of GH would alter expression of JAK2, we utilized a dynamic model of pulsatile GH infusion that mimicked the early pattern of circulating GH expressed in younger, rapidly growing birds (high amplitude peaks with an inter-peak interval of 90 min). A 120-122 kDa protein in liver and muscle, and a dominant 130-136 kDa protein in the muscle, that was phosphorylated in response to GH, were specifically recognized by the JAK2 antibody. Chronic, pulsatile infusion of cGH into 8-week-old chickens was associated with increased abundance and tyrosine phosphorylation of JAK2 protein in both liver and muscle (P < 0.05), which were GH dose-dependent, and mirrored previously reported biological responses for the same birds [Vasilatos-Younken, R., Zhou, Y., Wang, X., McMurtry, J.P., Rosebrough, R.W., Decuypere, E., Buys, N., Darras, V.M., Van Der Geyten, S., Tomas, F., 2000. Altered chicken thyroid hormone metabolism with chronic GH enhancement in vivo: Consequences for skeletal muscle growth. Journal of Endocrinology 166, 609-620.]. In summary (1) JAK2 immunoreactive proteins that associate with the GHR and are tyrosine phosphorylated in response to GH were identified in an avian hepatoma cell line and expressed in both GH responsive (liver) and "non-responsive" (skeletal muscle) tissues; (2) tyrosine phosphorylation of JAK2 occurred within minutes of exposure to a single i.v. injection of GH in vivo in muscle but not liver of 8-week-old birds; and 3) there were GH dose-dependent increases in abundance of JAK2 protein and tyrosine phosphorylation in both tissues when chronically exposed to GH in a physiologically relevant pattern, that mirrored dose-dependent biological responses, including alterations in the pathway of thyroid hormone metabolism, previously reported. Enhanced JAK2 suggests one possible mechanism whereby chronic, physiologically appropriate exposure to the ligand enhances GH biological action via increased abundance of a key upstream component of the signal transduction pathway.

A low residue nutritive supplement as an alternative to feed withdrawal in broilers: efficacy for gastrointestinal tract emptying and maintenance of live weight prior to slaughter

Experiments were conducted to evaluate the production response to a solid phase, nutritive supplement used as an alternative to feed withdrawal in broiler chickens and its effect on gastrointestinal tract (GIT) residue. Three treatments were applied: a conventional 12-h feed withdrawal (control); provision of a highly digestible, carbohydrate-based feed withdrawal supplement (FWS) with no added protein source (FWS0); and provision of FWS containing 16% CP as a highly digestible protein source (FWS16). Both FWS treatments were designed to be highly and rapidly soluble, were formulated to result in nominally lower GIT residues, and were withdrawn for only 3 h prior to slaughter. Visual assessment of segments of the GIT at slaughter indicated no significant differences among treatments in the degree of emptiness of the crop, gizzard, and colon, whereas intestinal contents of both FWS groups were less (P < 0.05) than those of the control group. With or without prior acclimation to supplements, live weight losses for both FWS groups were consistently and significantly less than for the control group (P < 0.05). In birds acclimated to the supplement, hot eviscerated and chilled carcass weights and deboned breast meat yield were greater for FWS16 than for the control group (P < 0.05). Carcass water uptake during chilling was similar or lower for FWS treatments compared to controls so that the effect of supplement on improving product yield was not due to excessive water uptake. These data indicate that the provision of a highly digestible feed withdrawal supplement enhanced lower GIT emptying, reduced live weight loss, and in some instances improved product yield without the need for a prolonged period of feed withdrawal.

Oral lavage with polyethylene glycol reduces microbial colonization in the gastrointestinal tract of broilers

Oral lavage of 7-wk-old broiler chickens with polyethylene glycol (PEG) was conducted to induce rapid evacuation of the gastro-intestinal tract (GIT) before processing. Three groups of birds were fed ad libitum (FF), subjected to feed withdrawal 12 h before processing (FW), or received 115 mL of PEG by oral lavage 3 h before processing (PEG(L)). The crop, a section of small intestine, and the right cecum were aseptically collected for determination of contents and Gram-negative bacilli (GNB) counts. The PEG(L) effectively cleansed the upper GIT and intestine of treated birds within 3 h before processing. However, the ceca were not completely empty for all the birds subjected to PEG(L). The PEG(L) group had a significantly lower crop and cecal GNB concentrations than the FW group. Birds on FW and PEG(L) treatments had significantly lower GNB concentrations in the small intestine than FF birds. Polyethylene glycol resulted in complete evacuation of the upper GIT, as well as the intestine, within 3 h of use, and significantly reduced GNB concentrations.

The distribution of neuropeptide Y gene expression in the chicken brain

Neuropeptide Y (NPY) is demonstrated to play an important role in central control of voluntary feed intake (FI) of a variety of species. The commercial broiler chicken has been intensively selected over generations for increased body weight, achieved largely through increased FI. This has resulted in a contemporary animal that does not regulate FI to maintain energy balance, and represents a model for hyperphagia and obesity if allowed unrestricted access to feed. In the present study, the distribution of NPY mRNA was mapped in the brain of juvenile, broiler-strain chicken, and results interpreted in the context of previous data for strains that do not exhibit hyperphagia. NPY mRNA was widely distributed in the broiler brain, and highly expressed in the hippocampus, nucleus commissurae pallii, infundibular hypothalamic nucleus, nucleus pretectalis pars ventralis and neurons around the nucleus rotundus. Moderately labeled neurons were found in the lateral septal organ, nucleus periventricularis hypothalamus and nucleus paraventricularis magnocellularis. The pallium exhibited only sparse labeling. Generally, the distribution of cell groups expressing NPY mRNA was consistent with those regions exhibiting NPY immunoreactivity, and also matches the distribution of receptor binding sites reported in the literature for the chicken brain. This suggests that NPY may be involved in functions controlled by these regions. The observation of NPY gene expression in brain regions involved in appetite regulation is consistent with the recognized importance of NPY in FI regulation in a variety of species, and with the chronic hyperphagia, characteristic of the broiler.

Evidence of a role for neuropeptide Y and monoamines in mediating the appetite-suppressive effect of GH

Among the many responses to GH administration is suppression of voluntary feed intake (FI) in some species, attributed to improvement in the efficiency of nutrient utilization and, therefore, reduced need for ingested substrates. Commercial broiler chickens have been genetically selected for generations for rapid growth, realized largely via the major correlated response of increased voluntary feed consumption. Neuropeptide Y (NPY) and monoamines play very important roles in the central regulation of feeding. Preliminary studies from our laboratory suggest that the appetite-suppressive effect of GH may be independent of its actions as a repartitioning agent, and may involve alterations in NPY expression at the pre-translational level. The purpose of this investigation was to explore the dose-response nature of the appetite-suppressive effect of GH in juvenile broilers, and the possible involvement of NPY and monoamines in this process. A GH dose-response study was conducted using 8-week-old female broilers infused i.v. with GH in a pulsatile pattern for 7 days at 0, 10, 50, 100 or 200 microgram/kg body weight per day. Hypothalamic NPY and epinephrine (EP) concentrations decreased in a dose-related manner with GH. At the highest dosage, voluntary FI decreased 19% (P<0.05) and hypothalamic NPY mRNA decreased approximately 50% in the infundibular nuclei and midline region (P<0.0001). In contrast, birds pairfed to the high-GH dosage group did not differ from controls, verifying that changes in NPY and monoamines were not secondary to reduced FI. We conclude that hypothalamic NPY and EP are likely candidates to explore further as mediators of the appetite-suppressive effect of GH.

Altered chicken thyroid hormone metabolism with chronic GH enhancement in vivo: consequences for skeletal muscle growth

In contrast to most vertebrates, GH reportedly has no effect upon somatic growth of the chicken. However, previous studies employed only one to two dosages of the hormone, and limited evidence exists of a hyperthyroid response that may confound its anabolic potential. This study evaluated the effects of 0, 10, 50, 100 and 200 microgram/kg body weight per day chicken GH (cGH) (0-200 GH) infused i.v. for 7 days in a pulsatile pattern to immature, growing broiler chickens (9-10 birds/dosage). Comprehensive profiles of thyroid hormone metabolism and measures of somatic growth were obtained. Overall (average) body weight gain was reduced 25% by GH, with a curvilinear, dose-dependent decrease in skeletal (breast) muscle mass that was maximal (12%) at 100 GH. This profile mirrored GH dose-dependent decreases in hepatic type III deiodinase (DIII) activity and increases in plasma tri-iodothyronine (T(3)), with bot! h also maximal (74 and 108% respectively) at 100 GH. No effect on type I deiodinase was observed. At the maximally effective dosage, hepatic DIII gene expression was reduced 44% versus controls. Despite dose-dependent, fold-increases in hepatic IGF-I protein content, circulating IGF-I was not altered with GH infusion, suggesting impairment of hepatic IGF-I release. Significant, GH dose-dependent increases in plasma non-esterified fatty acid and glucose, and overall decreases in triacylglycerides were also observed. At 200 GH, feed intake was significantly reduced (19%; P<0.05) versus controls; however, additional control birds pair-fed to this level did not exhibit any responses observed for GH-treated birds. The results of this study support a pathway by which GH impacts on thyroid hormone metabolism beginning at a pretranslational level, with reduced hepatic DIII gene expression, translating to reduced protein (enzyme) ex! pression, and reflected in a reduced level of peripheral T(3)-degrading activity. This contributes to decreased conversion of T(3) to its inactive form, thereby elevating circulating T(3) levels. The hyper-T(3) state leads to reduced net skeletal muscle deposition, and may impair release of GH-enhanced, hepatic IGF-I. In conclusion, GH has significant biological effects in the chicken, but profound metabolic actions predominate that may confound positive, IGF-I-mediated skeletal muscle growth.

Dietary protein effects on the broiler's adaptation to triiodothyronine

The purpose of this experiment was to study the effects of dietary protein on metabolic adaptations in birds given triiodothyronine (T3) at 28 d of age. Knowledge about the role of dietary protein in thyroid metabolism is lacking. Male broiler chickens were fed diets containing either 120 or 300 g crude protein/kg from 7 to 28 d. At this time, one-half of each group was given that diet supplemented with 1 mg/kg T3. Birds were sampled at 0, 2, 5, 7, 9 and 12 d following the initiation of the T3 treatments. Measurements taken at these intervals included in vitro lipogenesis (IVL), growth and feed consumption, hepatic enzyme activities and plasma thyroid hormones and metabolites. As expected, IVL was greater at 28 d in birds fed the lower level of protein. Moreover, when T3 was added to either diet, IVL decreased by 50% after 5 d. Plasma IGF-I and T4 were greater while T3 and GH were less when birds were fed the higher level of crude protein. Plasma T3 increased and T4 decreased 3 d following the addition of T3 to diets containing either level of crude protein. Most metabolic changes in response to feeding T3 occurred within 2 to 5 d, suggesting that changes in intermediary metabolism preceded morphological changes that we have previously seen. In addition, dietary protein levels may not affect adaptive responses to T3.

Influence of dietary protein on insulin-like growth factor binding proteins in the chicken

We determined the effect of dietary protein on the distribution of insulin-like growth factor (IGF) binding proteins in chicken plasma. Three groups of male broilers (n = 6 per group) were fed (ad libitum) isocaloric diets containing 12, 21 or 30% dietary protein. Birds were fed respective diets beginning at 7 days of age and killed at 28 days. No differences were observed between adequate (21%) and high (30%) protein intakes for any of the parameters investigated (growth criteria, plasma levels of IGF-I, growth hormone or IGF-binding proteins). Feeding protein deficient diets (12%) resulted in a 34% decrease in body weight, 17% decrease in feed intake and a 39% increase in feed/gain ratio. IGF-binding proteins in plasma samples were separated by SDS-PAGE and transferred to nitrocellulose sheets. Nitrocellulose blots were probed with [125I]chicken IGF-II. Four regions of binding activity corresponding to 70, 43, 30 and 24 kDa were observed in all samples. Birds consuming 12% dietary group protein had less than 50% of the 43-kDa binding activity of birds consuming 21 or 30% dietary protein. The 30-kDa binding activity was 42% lower in the 12% dietary protein group compared to birds consuming adequate protein. In contrast, 70- and 24-kDa binding activities were not influenced by dietary protein. Chickens consuming 12% dietary protein had higher levels of growth hormone and lower levels of IGF-I than those consuming 21 or 30% dietary protein. These data indicate that in chickens, the circulating levels of at least two independent IGF-binding proteins are influenced by dietary protein.

New insights into the mechanism and actions of growth hormone (GH) in poultry

Despite well documented anabolic effects of GH in mammals, a clear demonstration of such responses in domestic poultry is lacking. Recently, comprehensive dose-response studies of GH have been conducted in broilers during late post-hatch development (8 to 9 weeks of age). GH reduced feed intake (FI) and body weight gain in a dose-dependent manner, whereas birds pair-fed to the level of voluntary FI of GH-infused birds did not differ from controls. The reduction in voluntary FI may involve centrally mediated mechanisms, as hypothalamic neuropeptide Y protein and mRNA were reduced with GH, coincident with the maximal depression in FI. Growth of breast muscle was also reduced in a dose-dependent manner. Circulating IGF-I was not enhanced by GH, despite evidence that early events in the GH signaling pathway were intact. A GH dose-dependent increase in circulating 3,3',5-triiodothyronine(T3) paralleled decreases in hepatic 5D-III monodeiodinase activity, whereas 5'D-I activity was not altered. This confirms that a marked hyperthyroid response to GH occurs in late posthatch chickens, resulting from a decrease in the degradative pathway of T3 metabolism. This secondary hyperthyroidism would account for the decreased skeletal muscle mass (52) and lack of enhanced IGF-I (53) in GH-treated birds. Based upon these studies, it is now evident that GH does in fact have significant effects in poultry, but metabolic responses may confound the anabolic potential of the hormone.

Effect of feed withdrawal or challenge with Pasteurella multocida on growth, blood metabolites, circulating growth hormone, and insulin-like growth factor-I concentrations in eight-week-old turkeys

The daily effects of feed withdrawal or a bacterial disease (Pasteurella multocida; PM) challenge was studied in a slow-growing line of turkeys. The following groups (n = 6 birds/group) were sampled for up to 13 d: untreated control (CON), 4-d feed withdrawal followed by refeeding (FAST), a group that succumbed within the first 2 to 3 d after PM challenge (E-DEAD), a group that succumbed 8 to 9 d after PM challenge (L-DEAD), a group that survived the PM challenge (SUR), and a group treated with both PM challenge and 4-d feed withdrawal followed by refeeding (FAST/CHAL). Daily feed intake and BW gains were markedly reduced in the E-DEAD and L-DEAD groups immediately and 3 d after PM challenge, respectively. Feed intake and BW gain between CON and SUR groups of turkeys were not different throughout the trial. The turkeys in the FAST group followed the expected feed withdrawal and refeeding patterns for feed intake and BW loss or gain. The FAST/CHAL turkeys consumed the minimal amount of feed to maintain BW after refeeding. Plasma uric acid sharply increased 1 d prior to death in both E-DEAD and L-DEAD groups of turkeys. Plasma uric acid also increased each consecutive day during fasting in the FAST and FAST/CHAL groups of turkeys. Plasma growth hormone was measured in only the CON and FAST groups and increased from about 40 to 85 ng/mL in the FAST group during fasting but returned to control levels within 1 d of refeeding. Circulating plasma insulin-like growth factor-I (IGF-I) decreased from about 17 to 5 ng/mL in the PM-challenged (E-DEAD, L-DEAD, and FAST/CHAL groups) and FAST groups. The concentration of IGF-I returned to prefeed withdrawal levels within 3 d of refeeding the FAST group of turkeys. It was concluded that 1) turkey poults that were not susceptible to the PM challenge generally maintained physiological functions at control bird levels, 2) susceptible turkey poults generally exhibited depressed feed intake and BW gains, and 3) poults challenged with both feed withdrawal and PM treatment responded differently than poults challenged with either feed withdrawal or challenge with PM. The depletion of energy intake and mobilization of energy stores in susceptible poults might have contributed to the rate at which PM caused the poults to die.

Dietary fat and protein interactions in the broiler

An experiment was conducted to study the interrelationships between dietary fat and protein levels in the regulation of lipid metabolism in the broiler chicken. Birds were fed diets containing 300, 600, or 1,200 kcal ME from fat (corn oil) with either 124 or 190 g CP/kg. Two additional experimental diets contained 234 or 285 g CP and 300 kcal ME from fat. Regardless of fat level, birds fed the diets containing 124 g CP/kg weighed less and were less efficient than birds fed diets containing 190 g CP/kg. The diet containing 600 kcal as fat decreased lipogenesis and malic enzyme activity (P < 0.05) in birds fed the diet containing 190 g CP/kg diet, but not in birds fed the diet containing 124 g CP/kg. Birds fed the latter level of protein required at least 1,200 kcal as fat to express any significant decrease in lipogenesis or malic enzyme activity (P < 0.05). Dietary fat did not affect plasma levels of triiodothyronine (T3), thyroxine (T4), or insulin-like growth factor-I (IGF-I). Feeding diets containing 124 g CP/kg resulted in decreased plasma T4 and IGF-I and elevated T3 (P < 0.05). Increasing dietary protein (compared to increasing dietary fat) increased body weights, IGF-I, T4 and decreased lipogenesis, malic enzyme activity, and T3. Both of these regimens involve decreasing dietary carbohydrate at equal rates, but results differed. Although replacement of dietary carbohydrates with either fat or protein reduce precursors for fat synthesis, both energy sources have additional unique effects on metabolism. Dietary protein levels modulate metabolic effects of dietary fat.

Effects of growth hormone and pair-feeding on leptin mRNA expression in liver and adipose tissue

Previous research has reported that elevations in circulating growth hormone (GH) levels in meat-type chickens depresses feed intake (FI) more than 30%. It is known that the product of the obese gene, leptin, functions to regulate FI and energy expenditure. To investigate the effect of GH on leptin gene expression, broiler chickens were infused with recombinant chicken GH. To separate any secondary effects of a GH-induced reduction in FI on leptin expression, groups of birds were pair-fed to an average level of voluntary intake similar to GH-treated birds, but received no GH treatment. GH treatment induced a dose-dependent increase in liver leptin gene expression, as measured by reverse transcriptase-polymerase chain reaction, whereas leptin expression in adipose tissue was unchanged. Conversely, in chickens pair-fed (feed-restricted) there was a decrease in leptin gene expression in both tissues. These results provide evidence of a direct effect of GH on leptin gene expression, which is independent of any effects on intake attributable to GH-treatment, and suggest differential regulation of leptin expression between adipose tissue and liver. The results of these experiments provide the first evidence of a relationship between GH and leptin in domestic birds.

Absence of growth hormone-induced avian muscle growth in vivo

Growth hormone (GH) clearly has the potential to dramatically enhance skeletal muscle accretion in red meat animals such as swine. It is generally accepted that this anabolic effect is mediated by insulin-like growth factor-I (IGF-I), a potent stimulator of proliferation and differentiation of satellite cells that are important for myofiber hypertrophy and for regeneration in postnatal muscle tissue. All available evidence suggests that the capacity for IGF-I-mediated actions of GH on avian myogenic cells is intact, and recent evidence is accumulating that GH may even have direct effects on avian skeletal muscle satellite cell proliferation and differentiation. However, with little exception, exogenous GH does not improve skeletal muscle mass, carcass protein, or any measure of muscle anabolism in domestic poultry. A primary lesion would appear to be the inability of GH to induce significant increases in circulating IGF-I concentrations in sexually immature, growing poultry. This is the case despite clear evidence of GH binding to hepatic receptors, GH-induced tyrosine phosphorylation of Janus kinase 2 (JAK2), and GH-induced expression of hepatic IGF-I mRNA and protein. Factors that should be explored with respect to this apparent discrepancy are discussed, including the regulation of IGF-I release, uptake, and interaction with cell-associated IGF binding proteins or receptors. In addition to its growth-promoting effects via IGF-I, GH has direct metabolic effects that are expressed as changes in circulating regulatory hormone and metabolite concentrations. The possibility that such changes may influence IGF-I release and action is also proposed.

Relative insensitivity of avian skeletal muscle glycogen to nutritive status

Previous studies in avian species have reported time-dependent losses in muscle glycogen with prolonged feed withdrawal (FW). However, cervical dislocation was used to collect tissues, a method that results in significant involuntary muscle convulsions. In this study, cervical dislocation alone was found to reduce muscle glycogen by 23%, therefore, barbiturate overdose was used to collect tissue samples before and after FW, at the end of refeeding, and from continuously fed controls at each interval. Additionally, plasma samples from 6-wk-old male chickens were taken at the initiation and end of a 24-hr feed withdrawal, and at various times during refeeding. After 24 hr of FW, liver glycogen decreased markedly (77%; P < 0.05), whereas muscle glycogen decreased slightly and transiently, such that it returned to and remained at control levels, even after prolonged (72 hr) FW. Plasma glucose was decreased, whereas glucagon was elevated after a 24-hr feed withdrawal (P < 0.05), when compared with control concentrations. Muscle glycogen levels were not significantly increased over control levels after refeeding, but liver glycogen was increased by 380% (P < 0.05). Feed deprivation followed by refeeding resulted in increased circulating insulin and glucose levels when compared with control levels. Therefore, by using methods of tissue collection that ensure that muscle glycogen determinations are not confounded by artifactual degradation, these results verify that regulation of avian muscle glycogen stores is similar to that in mammals.

Further studies on carry-over effects of dietary crude protein and triiodothyronine (T3) in broiler chickens

Indian River male broiler chickens growing from 7 to 28 d of age were fed on diets containing either 120 or 210 g crude protein and 0 or 1 mg triiodothyronine (T3)/kg diet to study in vitro lipogenesis (IVL). In addition, a carry-over period (180 g crude protein/kg diet from 28 to 40 d of age) was used to test the persistence of prior treatment effects. The higher protein level increased, but T3 decreased (P < 0.01) growth and feed consumption at 28 d of age. The lower protein level increased (P < 0.05) and T3 decreased IVL in 28-d-old chickens. These effects were only sustained for 6 d following the switch to a common diet at 28 d. IVL at 40 d of age was not affected by either crude protein or T3 fed during the 7-28 d period. The higher protein level increased plasma insulin-like growth factor-1 during the period from 7 to 28 d; however, this effect lasted for only 6 d following the switch to a common diet. Plasma growth hormone (GH) at 28 d of age was inversely related to dietary protein level. Changing to a common level of crude protein did not change plasma GH values at 12 d, indicating that the nutritional state of the young chicken may affect GH at a later period of life. Metabolic changes noted in this study were rapid and maintained for a short period of time following the feeding of a common diet.

Experimental reproduction of a spiking mortality syndrome of turkeys

Two-day-old turkey poults were inoculated with either a chicken embryo homogenate used previously to produce spiking mortality syndrome in chickens (the "Oakwood Agent") or an intestine-pancreas homogenate collected from field turkeys with the syndrome known as spiking mortality of turkeys. Twelve days postinoculation, the mean plasma insulinlike growth factor-1 (IGF-1) level and mean body weights were significantly depressed, and the mean plasma growth hormone level was significantly elevated, in the poults receiving the turkey-derived homogenate (P < or = 0.0003), as was previously reported in chickens with spiking mortality syndrome. The depression in plasma IGF-1 levels may explain the runting seen in poults that survive spiking mortality of turkeys in the field. Following a 4-hr fast and a brief cool water spraying, poults exhibited clinical signs indistinguishable from those of chicks with spiking mortality syndrome. However, plasma glucose levels in the affected poults were within the normal range, unlike chickens with spiking mortality syndrome. Immunohistochemistry on formalin-fixed intestines, ceca, and bursae produced positive staining using an arenavirus antibody in epithelial cells of poults inoculated with the turkey homogenate and those inoculated with the Oakwood Agent. Tissues of uninoculated controls were negative. Poults inoculated with the Oakwood Agent did not show noticeable disease.

Tissue-specific alterations in insulin-like growth factor-I concentrations in response to 3,3',5-triiodo-L-thyronine supplementation in the growth hormone receptor-deficient sex-linked dwarf chicken

Insulin-like growth factor-I (IGF-I) mediates many of the effects of growth hormone (GH). The regulation of IGF-I, independent of GH, is methodologically difficult to assess in vivo, as hypophysectomy results in derangement of many pituitary hormone axes in addition to GH, and a gene knockout model is not available. The recessive sex-linked dwarfing (SLD) gene (dw) in chickens results in a lack of functional target tissue GH receptors due to a variety of molecular defects, which provides a unique model for evaluating GH-independent regulation of IGF-I. In the present study, the impact of 3,3', 5-triiodo-l-thyronine (T3) on circulating and tissue IGF-I was determined in normal versus SLD birds. Adult, nonovulatory female normal and SLD chickens were restrict-fed 40 g of feed/kg bw/day containing 0, 0.5, or 1.0 ppm T3, resulting in supplementation levels of 0 (control), 20 (low dose), or 40 (high dose) microg T3/kg bw/day for 10 days. Samples of GH target tissues including liver, abdominal fat pad, skeletal muscle (pectoralis major), and spleen were extracted and assayed for IGF-I. Plasma T3, T4, GH, and IGF-I were determined by homologous RIA. Tissue GH binding was determined for hepatic membranes by radioreceptor assay. Under control conditions, dwarf chickens were markedly hypersomatotropic (33.3 +/- 4.1 ng GH/ml plasma; mean +/- SEM) compared to normals (2.4 +/- 3.9 ng/ml), and T3 supplementation reduced this to normal levels. Despite the high circulating level of GH in dwarfs, plasma IGF-I was low compared to normal controls (dwarfs 1.5 +/- .9 ng/ml; normals 5. 3 +/- .9 ng/ml; P = 0.004), but this difference was eliminated with low-dose T3. In this study, tissue IGF-I was undetectable in liver and pectoralis muscle in adults (55 weeks of age) of both genotypes, under all treatments. In contrast, adipose tissue IGF-I was relatively high and did not differ (P = 0.84) between genotypes under control conditions (normals 776.5 +/- 236.7; dwarfs 844.6 +/- 236.7 pg/mg protein), but was increased in normals and decreased in dwarfs, resulting in higher levels (P = 0.02) in the normal (1249.9 +/- 200.0 pg/mg protein) than in the dwarf genotype (558.4 +/- 200.0 pg/mg protein) at the higher level of T3 supplementation. This relationship was somewhat reversed in spleen, where T3 tended to decrease tissue IGF-I concentration in normals and increase it in dwarfs. The low level of plasma IGF-I despite nonmeasureable hepatic IGF-I tissue concentrations suggests that IGF-I synthesis by extrahepatic tissues contributes to the circulating pool of IGF-I. The relatively high control levels of adipose tissue IGF-I in the dwarf genotype further suggest that considerable IGF-I synthesis exists that is GH-independent in this extrahepatic tissue. The presence of GH action, however, may mediate the effects of other hormones that can influence local IGF-I production in this tissue, as reflected by the differential response to T3 supplementation between genotypes. The tissue-specific nature of the effect of T3 on IGF-I production supports an additional point of regulation of hormone action at the target tissue level.

Effect of exogenous chicken growth hormone (cGH) administration on insulin-like growth factor-I (IGF-I) gene expression in domestic fowl

The effects of chicken growth hormone (cGH) infusion on insulin-like growth factor (IGF-I) gene expression in rapidly-growing, meat-type chickens was investigated. Chicken GH was infused either continuously or in a pulsatile fashion to 8-week-old birds during a 7-day period. Following cGH infusion, both IGF-I peptide and IGF-I mRNA content were measured in selected tissues. Steady-state IGF-I mRNA abundance was determined by a solution hybridization nuclease protection assay using total cellular RNA obtained from liver, heart, kidney, spleen, epiphyseal growth plate cartilage, gastrocnemius and pectoralis muscles. Continuous infusion of cGH elicited a two-fold increase in IGF-I peptide concentration in the kidney (P < 0.05), while all other tissues remained unchanged by cGH treatment under this infusion pattern. Pulsatile cGH infusion produced a two-fold increase in IGF-I peptide content in the liver, gastrocnemius, and pectoralis muscles (P < 0.05). In contrast with the levels of IGI-I peptide, relative steady-state IGF-I mRNA content was two-fold higher in liver and spleen of birds treated continuously with cGH, but was decreased to 35 and 55% of control birds in heart and pectoralis muscle. Pulsatile cGH infusion resulted in a 64% increase in IGF-I mRNA in the liver and remained unchanged in other tissues. Under both patterns of administration, changes in IGF-I mRNA were not reflected by changes in tissue IGF-I peptide levels. Overall correlations between tissue IGF-I mRNA and peptide levels were low and not significant in the tissues studied, except for liver under pulsatile infusion, in which IGF-I peptide levels paralleled changes in IGF-I mRNA. We conclude that, in chickens, exogenous cGH treatment stimulates hepatic IGF-I transcription and translation only when the pattern of infusion mimics the natural episodic pattern of GH secretion. The low correlation between IGF-I peptide and mRNA levels in extra-hepatic tissues may indicate differential responsiveness to GH in birds, and that in some tissues IGF-I levels are under GH-independent transcriptional controls.

Responses to exogenous pulsatile turkey growth hormone by growing 8-week-old female turkeys

A study was conducted in turkeys to determine the effects of pulsatile infusion of turkey growth hormone (tGH) on growth, feed conversion, carcass component parts, carcass composition, plasma metabolite concentrations, and other hormones associated with growth. Female turkeys, 8 weeks of age, were dually cannulated via the right jugular for intermittent (10 min every 2 hr) infusion of tGH at a low dosage (4.5 micrograms tGH/infusion or 54 micrograms/day), a high dosage (18 micrograms tGH/infusion or 216 micrograms/day) or vehicle infused controls (vehicle, 0.025 M NaHCO3, 0.025 M Na2CO3 + 5 mg/ml NaCitrate, pH 9.4). Treatment was for 18 days. The second cannula was used to serially bleed the turkeys (5 or 10 min between samples) at 4 and 16 days of treatment to determine concentrations of GH, glucose, triacylglycerides (TG) non-esterified fatty acids (NEFA), and uric acid (UA). Overall GH was increased 74% above the control group in the low and 195% in the high treatment group. Baseline GH was increased 52% in the high group above the control group. The amplitude of GH peaks increased 292% in the low, and 574% in the high group above the amplitude of naturally occurring peaks in the control group. Infusion of tGH for 18 days did not affect overall daily gain, feed conversion, final body weight, tibiotarsus length, weights of pectoralis major, pectoralis minor, gastrocnemius or biceps femoris muscles, or weights of liver and offal. Abdominal fat pad weight (70% decrease), and percentages of carcass fat (4.9% decline) and carcass dry matter (2.3% decline) were lower in the high treatment group. Plasma TG and glucose were unaffected by treatment. Overall plasma NEFA concentration was increased in the high treatment group, and this increase was associated with an increased in the baseline concentration and incidence of pulses of NEFA, but not with the amplitude concentration of NEFA pulses. The dynamic nature of plasma NEFA concentration observed in this study suggests single time point measurements of this metabolite may not appropriately detect treatment effects. Plasma overall uric acid (UA) was decreased in the high treatment group in comparison to the control group, and this decrease was associated with a decrease in the baseline concentration of UA but not in the amplitude concentration nor incidence of UA pulses. Plasma insulin-like growth factor-I (IGF-I) concentrations were increased in the low treatment group at 4 but not at 16 days of treatment.(ABSTRACT TRUNCATED AT 400 WORDS)

Proposed mechanisms for the regulation of growth hormone action in poultry: metabolic effects

Growth hormone (GH) administration to nonruminant red meat animals markedly alters carcass composition so that dramatic reductions in adipose tissue accretion and enhancement of lean tissue growth occur. These repartitioning effects of GH in the pig are reported to reflect antagonism of the lipogenic effect of insulin on adipose tissue, the primary site of fatty acid synthesis in this species, so that glucose disposal and utilization by adipose tissue are markedly reduced, and substrate availability to muscle is increased. In poultry, a significant positive response to GH administration is not consistently achieved, and factors such as posthatch period of development and the pattern of tissue exposure to GH are important determinants of the response to GH enhancement. This may relate to the status of target tissue GH receptors that appear subject to down regulation in the adult chicken. Sensitivity of the bird to the appetite-suppressive effects of GH and interaction between this effect and energy intake have recently been demonstrated and need to be further explored. Growth hormone clearly influences hepatic lipogenesis and net lipid deposition in the broiler chicken. However, future research emphasis on the regulation of GH receptor binding activity and gene expression and their relationship to GH action, as well as on newer components of the GH axis such as GH-binding proteins, will help to clarify controlling mechanisms in poultry.

Markedly reduced pancreatic glucagon levels in broiler chickens with spiking mortality syndrome

Pancreata from 19 hypoglycemic field broilers with spiking mortality syndrome and 19 clinically normal field broilers with normal blood glucose levels were collected and quick-frozen in liquid nitrogen immediately after the chicks were bled and killed. All chicks were 16 days old and were of the same genetic cross. Pancreata were weighed, and acid-alcohol extractions were made on each specimen. Radioimmunoassays for glucagon levels were made on each extract. Mean pancreatic glucagon content of the hypoglycemic chicks was depressed 14-fold (93.1%) compared with that of the non-hypoglycemic group. There was a close correlation between plasma glucose levels and pancreatic glucagon levels (P = 0.0001).

Isolation and localization of basic fibroblast growth factor-immunoreactive substance in the epiphyseal growth plate

Previous research in our laboratory has shown basic fibroblast growth factor (bFGF) to be a permissive mitogen for isolated avian growth plate chondrocytes. The present study was conducted to determine whether bFGF is present in avian growth plate and, if present, to determine its localization within the tissue. Immunohistochemical studies revealed that bFGF is present in the resting proliferative and hypertrophic calcifying zones of the growth plate but is absent from the prehypertrophic zone. Basic FGF appears to be associated with the extracellular matrix of the proliferative zone, but it is predominantly intracellular in the hypertrophic and mineralizing zone chondrocytes. Partial purification of cartilage-derived bFGF was performed on crude extracts of cartilage using heparin-Sepharose affinity chromatography. The presence of bFGF in the heparin-Sepharose column fractions was confirmed by immunoblotting and radioimmunoassay. Furthermore, western blot analysis of the extracts showed multiple protein bands having bFGF immunoreactivity, in the molecular weight range 14.4-18 kD. The data support the hypothesis that bFGF has a dual role in the growth plate. In the proliferative zone it acts as a chondrocyte mitogen, whereas when released from terminal hypertrophic chondrocytes, bFGF may serve as a chemotactic signal for metaphyseal blood vessel proliferation.

Effects of somatostatin on plasma growth hormone and metabolite concentrations in fed and feed-deprived young female turkeys

The sensitivity and magnitude of response to somatostatin-14 (SRIF-14) infusion in terms of changes in plasma concentrations of growth hormone (GH) and energy-related metabolites [nonesterified fatty acids (NEFA), glucose, and triacylglycerides (TG)] were determined in 9- to 11-wk-old fed or feed-deprived (FD; 20 h) female turkeys. The turkeys were sequentially infused with increasing doses of SRIF-14 (.0015 to 1.5 micrograms/min) concurrent with serial collection of blood samples (every 10 min). Plasma GH and NEFA concentrations were lower in fed than in FD birds. In fed birds only NEFA was minimally altered by SRIF-14 infusion. In FD birds, GH was decreased, but only at the highest dose of SRIF-14 (1.5 micrograms/min), whereas NEFA was decreased in a dose-dependent manner from .05 to 1.5 micrograms/min. Very rapid postinfusion rebounds of plasma GH and NEFA were observed in FD birds. Plasma glucose was not influenced by SRIF-14 in either fed or FD birds. Concentrations of plasma TG were depressed slightly by SRIF-14 in FD but not in fed birds. The present studies indicate that 1) FD birds are more sensitive to SRIF-14 infusion than are fed birds; 2) in FD birds, inhibition of lipolysis (indicated by plasma NEFA) is sensitive to lower dosages of SRIF-14 infusion than is inhibition of GH; and 3) SRIF-14 has little if any effect on TG and glucose metabolism.

Effects of glucagon infusion, alone or in combination with somatostatin, on plasma growth hormone and metabolite levels in young female turkeys under different feeding regimens

The lipolytic effect of glucagon alone or in combination with somatostatin-14 (SRIF-14) was studied in 9- to 11-wk-old female turkeys that either consumed feed ad libitum or were deprived of feed (FD) for 20 h. During the infusion of various doses of glucagon (.005 to 1.5 micrograms glucagon/min), blood samples were serially collected every 10 min for determination of plasma concentrations of growth hormone (GH) and energy-related metabolites [nonesterified fatty acids (NEFA), glucose, and triacylglycerol (TG)]. Glucagon infusion resulted in decreases (P < .05) in plasma GH in both groups of turkeys. During glucagon infusion, dose-dependent increases in both glucose and NEFA occurred, with greater relative increases in the ad libitum turkeys. In contrast, plasma TG was decreased by glucagon infusion in the ad libitum turkeys but unchanged in the FD turkeys. The effect of simultaneous infusion of SRIF-14 and glucagon on GH and NEFA concentrations varied depending on the previous hormonal treatment. Plasma glucose was not affected by SRIF-14 in either group of turkeys. The present studies show that: 1) glucagon is an important agent for directing carbohydrate and lipid metabolism in growing female turkeys; 2) SRIF-14 has little effect on carbohydrate metabolism, but does affect lipolysis in a complex manner with glucagon; and 3) in vivo, glucagon depresses plasma GH.

Effect of growth hormone, insulin-like growth factor I, basic fibroblast growth factor, and transforming growth factor beta on cell proliferation and proteoglycan synthesis by avian postembryonic growth plate chondrocytes

We examined the in vitro effects of pituitary-derived chicken growth hormone (cGH), recombinant human insulin-like growth factor-I (rhIGF-I), recombinant human basic fibroblast growth factor (rhbFGF), and porcine transforming growth factor beta (pTGF-beta) on proliferation ([3H]thymidine uptake) and matrix proteoglycan synthesis (35SO4 incorporation) by chicken epiphyseal growth plate chondrocytes. Factorial experiments were used to study the effect of these substances in a serum-free culture system. Basic FGF had to be present in the culture medium for mitogenesis to take place. In the presence of this peptide, TGF-beta, TGF-beta + IGF-I, and newborn calf serum (NCS) stimulated mitogenesis. The mitogenic activity of NCS could be duplicated by adding platelet-derived growth factor (PDGF) to the culture medium. For matrix synthesis, IGF-I was the key factor, with the addition of TGF-beta, TGF-beta+bFGF, or serum producing further stimulation in matrix synthesis. Using this culturing system, homologous cGH did not stimulate cell proliferation or proteoglycan synthesis. The lack of stimulatory activity of cGH was consistent, regardless of the age of the birds from which the chondrocytes were isolated, the zone of the growth plate, or the level of cGH used. None of the growth factors used in this study or several other systemic hormones were found to be permissive factors for GH to be active. Either other factors must be present for a direct effect of GH on growth plate chondrocytes, or the avian species differ from their mammalian counterpart.

Circulating IGF-I in plasma of growing male and female turkeys of medium and heavy weight lines

Plasma concentrations of insulin-like growth factor-I (IGF-I) were determined in male and female turkeys from a medium weight (RBC2) and a related heavy weight line (F) from 1 to 28 wks of age. At hatch, the concentrations of IGF-I were relatively low and not different between lines or sexes. During the neonatal period (1 to 7 wks), the concentrations of IGF-I increased and were higher in the faster growing F line and in males. During the juvenile period (8 to 15 wks) the concentrations of IGF-I were higher in males but not different between lines. During the preadolescent period (16 to 21 wks), the concentrations of IGF-I were higher in males but was not different between lines in males while the females of the RBC2 line had higher concentrations than females of the F line. During the adolescent period (22 to 28 wks) the concentrations of IGF-I were higher in males but was not different between lines in males while the females of the RBC2 line had higher concentrations than females of the F line. A phenotypic correlation (+.25) between plasma IGF-I and growth rate was present after statistical absorption of model effects during the neonatal period but not at the later ages. We conclude that IGF-I concentration was positively correlated with growth rate during the neonatal period, but that this relationship changed during the preadolescent and adolescent periods so that IGF-I concentrations were not related to growth rate in males but were negatively related to growth rate in females.

Restoration of juvenile baseline growth hormone secretion with preservation of the ultradian growth hormone rhythm by continuous delivery of growth hormone-releasing factor

The ability of continuously delivered GH-releasing factor (GRF) to enhance GH secretion while maintaining the normal ultradian GH rhythm was investigated. Synthetic human GH-releasing factor (hGRF(1-44)NH2) was continuously infused for 4 days by means of i.v. catheters to 11-week-old broiler chickens. At this age, overall endogenous GH secretion is low, and baseline GH is barely detectable. Six birds per treatment received vehicle (control), 0.324 mg hGRF(1-44)NH2/kg body weight per day (low dose) or 3.24 mg hGRF(1-44)NH2/kg body weight per day (high dose). After 4 days of GRF conditioning, concurrent with continued GRF infusion, serial blood samples were removed via atrial catheters at 15-min intervals for 6 h and GH plasma profiles determined. High dose GRF significantly increased GH plasma concentrations over tenfold compared with controls; however, most of this increase reflected an increase in basal GH, which was reinstated to juvenile baseline levels. Augmentation of pulse amplitude above this increased baseline was not proportionately as high, and failed to reach juvenile levels. The ultradian rhythm of GH was not altered by continuous GRF administration. Both low and high dose GRF treatments resulted in significant enlargement of the anterior pituitary gland. Total pituitary GH mRNA levels, although elevated over twofold by GRF treatment, were not significantly different from controls. Measures of plasma GH magnitude (overall and baseline mean, and peak amplitude) were significantly correlated with pituitary GH mRNA for control birds, but were not correlated for GRF treatments. Feed intake was markedly depressed (33%) on the high dose GRF treatment, in conjunction with total inhibition of body weight gain over the 4-day period of administration. Longitudinal bone growth and width of the epiphyseal growth plate were also significantly reduced by high dose GRF treatment, probably reflecting the reduced level of nutrient intake, despite high circulating concentrations of GH.

Adsorption of oviductal fluid proteins by the bovine sperm membrane during in vitro capacitation

125I-labeled oviductal fluid (ODF) proteins and antiserum to ODF were used to determine whether ODF proteins associate with the sperm membrane during in vitro capacitation. Luteal and nonluteal pools of ODF were obtained from oviduct catheters during the estrous cycle. Washed sperm (50 x 10(6) sperm/ml) were incubated up to 4 h in a protein-free modified Tyrode's medium (MTM), or MTM supplemented with 40% ODF, or 0.5 ng 125I-labeled ODF proteins. Solubilized sperm membrane proteins and incubation media containing ODF proteins were separated by gel electrophoresis. Membranes isolated from bovine sperm, previously incubated with ODF, adsorbed five 125I-proteins: A doublet at 85-95 kDa, and others at 24, 34, 53, and 66 kDa. The amount of 66 kDA 125I-protein associated with the sperm decreased during the incubation, whereas the amount of 85 to 95-kDa protein did not. Western blot analyses also detected the presence of ODF proteins (53, 66, 85-95, and 116 kDa) in solubilized membranes from sperm incubated in ODF. The 85 to 95-kDa protein in ODF decreased in apparent molecular weight by 5 kDa when associated with the sperm membrane. At 53 kDa, ODF proteins which associated with sperm were transformed from two to three separate proteins. These studies indicate that the surface of sperm is modified by adsorption of ODF proteins to the membrane during in vitro capacitation.

In vitro lipid metabolism, growth and metabolic hormone concentrations in hyperthyroid chickens

Indian River male broiler chickens growing from 7 to 28 d of age were fed on diets containing energy:protein values varying from 43 to 106 MJ/kg protein and containing 0 or 1 mg triiodothyronine (T3)/kg diet to study effects on growth, metabolic hormone concentrations and in vitro lipogenesis. In vitro lipid synthesis was determined in liver explants in the presence and absence of ouabain (Na+, K(+)-transporting ATPase (EC 3.6.1.37) inhibitor) to estimate the role of enzyme activity in explants synthesizing lipid. Growth and feed consumption increased (P < 0.01) when the energy:protein value decreased from 106 to 71 MJ/kg protein; however, both variables decreased as the value was further decreased from 53 to 43 MJ/kg protein. Triiodothyronine depressed (P < 0.01) growth, but not food intake. Large energy:protein diets (> 53 MJ/kg protein) and dietary T3 lowered (P < 0.01) plasma growth hormone. Large energy:protein diets (> 53 MJ/kg protein) increased (P < 0.01) lipogenesis, plasma growth hormone (GH) and decreased plasma insulin-like growth factor 1 (IGF-1). Also, T3 decreased plasma GH, IGF-1 in vitro lipogenesis. Ouabain inhibited a greater proportion of in vitro lipogenesis in those explants synthesizing fat at a high rate. Both dietary T3 and in vitro ouabain decrease lipogenesis, but, when combined, the effects are not cumulative.

Growth hormone and insulin-like growth factors in poultry growth: required, optimal, or ineffective?

With a continually expanding market for poultry meat products, increased production demands of as much as 50% by the Year 2000 have been predicted. Indications already exist that this magnitude of expansion is not likely to be met by increased production output and genetic selection alone, and that other methods of improving growth performance per bird via exogenous manipulation of the growth process are needed. Studies in mammalian species clearly demonstrate the importance of growth hormone (GH) and its potential for enhancing productivity in domestic mammals. However, the role of GH in growth of poultry appears to be much more complex. Taken collectively, studies to date indicate that significant, positive effects of GH on growth performance of normal, growing poultry are possible. Expression of such effects appear to be largely contingent on the period of posthatch development (late posthatch being more responsive than early), and the pattern of several key metabolic regulatory hormones resulting in response to GH. Such regulatory hormone responses are largely influenced by the pattern or magnitude of exposure (acute versus chronic) to GH in birds. At this time, the available information on the potential for insulin-like growth factors to enhance growth is limited, and further studies are needed before a definitive role for these peptides in growth and development of poultry can be assigned.

Identification of circulating growth hormone-binding proteins in domestic poultry: an initial characterization

Multiple growth hormone (GH)-binding proteins (GHBPs) were identified in serum and plasma samples from domestic chickens and turkeys. Proteins were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis on 10% acrylamide, 2.7% bis discontinuous gels under reducing conditions and electrotransferred to nitrocellulose paper. Western blots were incubated with 125I-labelled recombinant chicken GH (cGH) or bovine GH and GHBPs visualized by means of autoradiography. In fresh samples (less than 2 h from collection to gel electrophoresis), multiple minor high Mr bands were evident between approximately 72,000 and 175,000. Two major bands were observed at approximately 69,500 and 27,500. The latter is consistent with previous reports for the rat and mouse serum GHBPs based on nucleotide sequence analysis. The minor bands were essentially undetectable after storage at -25 degrees C for several months, and an additional major band at Mr approximately 52,500 appeared. The Mr-69,500 major protein contained N-linked carbohydrate, as determined by a reduction in molecular size by treatment with peptide N-glycosidase F. Binding of 125I-labelled GH was partially inhibited by co-incubation with 50 micrograms unlabelled pituitary-derived cGH/ml and excess unlabelled porcine GH as well as ovine prolactin, but not by bovine insulin. Non-specific binding of 125I-labelled GH by serum albumin was also observed. A comparison was made between these GHBPs and the hepatic GH receptor (e.g. molecular weight estimates, affinity for homologous versus heterologous GHs, cross-reactivity with prolactin, presence of N-linked carbohydrate). The origin and relationship among the various molecular weight species of GHBPs identified, and their potential role in regulation of the biological activity of GH in birds, remain to be determined.

Sex-linked and maternal effects on growth in chickens

A study was designed to estimate the contribution of various types of genetic variation in growth of chickens using populations that widely differed in growth rate. Populations tested included a commercially developed sire line (CM), a fertility-selected, broiler-type line (FS), and the pureline Jersey Giant (JG). A full set of F1 crosses and purelines of both sexes was used to estimate the following genetic effects: heterosis due to the autosomes, heterosis due to the sex chromosomes, average line effects, maternal effects, and additive sex linkage. Average line effects were highly significant beyond hatching for both body weight and shank length, with rank-order CM greater than FS, which was greater than JG. Significant differences between the sexes within a line were observed for CM and JG line effects, confirming the existence of sex-linked factors. There was no average heterosis or sex-by-heterosis interaction for growth-related traits, but specific heterosis was frequently significant. Maternal effects were sporadic and generally of little importance beyond hatching. Additive sex linkage, however, was highly significant and influenced body weight beyond hatching. These data indicate that the primary advantages in increasing growth via cross-breeding in chickens comes from average line effects and additive sex linkage. Heterosis and maternal effects can influence performance, especially in specific crosses, but these effects appear to be sporadic and of less importance than sex linkage.

Characterization of hepatic growth hormone binding in domestic poultry

Specific binding of 125I-recombinant chicken growth hormone (r-cGH) to avian hepatic crude membrane preparations was characterized in terms of time, temperature, and pH dependence of binding as well as by demonstration of specificity and dissociability of the binding phenomenon. Crude membranes (100,000g pellet) were prepared from livers of female, 4-week-old broiler-strain chickens and 24-week-old random-bred turkeys. Optimal conditions for binding in a 25 mM Tris-HCl, 10 mM CaCl2 0.5% BSA buffer system were determined to be 24 hr at 30 degrees, pH 7.0, for chicken membrane preparations and 36 hr at 30 degrees, pH 7.2, for turkey membrane preparations. Total specific binding was proportional to the concentration of membrane protein, and remained linear over the range of 200 to 1400 micrograms per tube (500-3500 micrograms/ml) for both chicken and turkey systems. Binding of 125I-r-cGH was reduced by addition of unlabeled, pituitary-derived cGH (p-cGH) (IC50 = 0.42 ng/tube/600 micrograms membrane protein for turkey; 3.8 ng/tube/600 micrograms membrane protein for chicken). Bovine GH (bGH) was an even more effective competitor than cGH, such that at approximately the IC50 for p-cGH, bGH displaced 83.5% of 125I-r-cGH. Bovine prolactin also competed with 125I-r-cGH; however, cross-reactivity was only 1% that of bGH. Rat TSH exhibited negligible and LH and FSH essentially no cross-reactivity in the avian system. Binding was reversible as indicated by dissociation of 75% of bound 125I-r-cGH from turkey preparations and complete dissociation from chicken preparations by 12 hr following addition of excess unlabeled hormone.

Effect of pulsatile or continuous administration of pituitary-derived chicken growth hormone (p-cGH) on lipid metabolism in broiler pullets

1. The effects of pulsatile and continuous intravenous administration of exogenous, pituitary-derived chicken growth hormone (p-cGH) on lipid metabolism and endocrine/metabolite levels of broiler-strain pullets were studied. 2. Eight-week-old pullets were administered p-cGH or vehicle over a 10 min period every 90 min for 7 days. 3. Pullets were also administered the same daily amount (123 micrograms/kg of body weight/day) continuously for 7 days. 4. Feed intake, body weight gain, in vitro lipogenesis and hepatic enzyme activities were determined with certain hormones identified with the control of growth. 5. Pulsatile p-cGH administration for 7 days lacked effect on weight gain, feed efficiency, muscle or bone development. 6. Abdominal fat pad size was decreased (P less than 0.05) by pulsatile but not continuous administration of p-cGH. Pulsatile p-cGH administration also decreased (P less than 0.05) in vitro lipogenesis. Liver malic enzyme and isocitrate dehydrogenase activities were increased (P less than 0.05) by pulsatile but not continuous administration of p-cGH. In contrast, glutamic oxaloacetic transaminase activity was increased by a continuous infusion of p-cGH. 7. Plasma concentrations of T4 corticosterone and triglycerides were decreased (P less than 0.05) by a pulsatile but not a constant infusion of p-cGH. 8. Plasma T3 and GH were increased (P less than 0.05) by pulsatile p-cGH compared to both a continuous infusion of p-cGH and the saline controls. 9. This study is the first to prove that in the broiler chicken, the pattern of exogenous p-cGH administration is a factor influencing in vitro responses to the hormone.

Pattern of growth and plasma growth hormone secretion in turkeys selected for increased egg production

Male and female turkeys of a slow-growing line selected for increased 180-day egg production (Line E) and its faster growing randombred control (RBC1) were sampled weekly for BW and plasma growth hormone (GH) content. Hatching weights were higher for RBC1 than Line E poults, but no difference was observed between sexes. The pattern of growth of the two lines, as described by the Gompertz equation, was different in magnitude of growth [BW at point of inflection (POI) and asymptote] but not in form (slope and age at POI and age at asymptote). Males achieved higher weights at POI and asymptote but took longer to reach these weights. Slope at POI was greater for females than for males. Plasma GH was higher in Line E than in RBC1 at hatching but higher in RBC1 than in Line E from Weeks 7 to 28. Males had higher concentrations of circulating plasma GH than females at all ages. The GH pool size was maximal at 5 wk for females and 10 wk for males. Maximal concentrations of circulating GH preceded maximal GH pool size by several weeks.

Ontogeny of growth hormone (GH) binding in the domestic turkey: evidence of sexual dimorphism and developmental changes in relationship to plasma GH

The post-hatch ontogeny of hepatic GH binding and its relationship to GH plasma profile characteristics in male and female turkeys of slow- (RBC-2) and fast-growing (F; selected from RBC-2) genetic lines were determined. Specific binding of 125I-labelled recombinant chicken GH to crude hepatic membrane preparations (100,000 g pellet) was determined at 2, 4, 8, 14 and 24 weeks of age for both total (occupied plus free; 4 mol MgCl2/l pretreatment) and free (without MgCl2 pretreatment) binding sites. Characteristics of the plasma GH profile were measured at each age by serial blood sampling through indwelling jugular vein catheters. When specific binding to either free or total sites was expressed on a whole organ basis (i.e. hepatic GH-binding capacity/bird), binding increased dramatically (P less than 0.0001) with increasing age over both lines and sexes. Total binding capacity (free plus occupied sites) per bird was greater for females than for males at 24 weeks of age (P less than 0.04), as birds reached sexual maturity, but did not differ between fast- and slow-growing lines at any age. Available binding capacity (free sites) per bird was greater for the faster growing F than RBC-2 line at the older ages when body size was most divergent (14 and 24 weeks of age; P less than 0.01, P less than 0.06 respectively), but did not differ between sexes. Correlation analysis at individual ages revealed a progressive change in the nature of the relationship between hepatic GH binding, plasma GH and somatic growth.(ABSTRACT TRUNCATED AT 250 WORDS)

Hepatomegaly induced by the pulsatile, but not continuous, intravenous administration of purified chicken growth hormone in broiler pullets: liver composition and nucleic-acid content

The present study determined the composition and nucleic-acid content of livers obtained from 11-wk-old, broiler-strain pullets infused with pituitary-derived chicken growth hormone (p-cGH) in either a pulsatile (Study 1) or continuous (Study 2) manner for 21 days. Pulsatile p-cGH administration resulted in a decrease in ratios for liver DNA to wet weight (P less than .01), DNA to protein (P less than .03), and DNA to RNA (P less than .002), compared with controls. Total RNA-to-liver ratio (P less than .003) and liver weight (P less than .007) were significantly elevated, compared with controls. Total grams of protein (P less than .0007), water (P less than .004), and ash (P less than .01) were also elevated, with no significant differences in the percentage of composition. Continuous growth-hormone (GH) administration resulted in a decrease in the DNA-to-protein ratio (P less than .04) and a modest increase in the mass of liver protein (P less than .11) in comparison with controls, suggestive of cell hypertrophy. On a mass and percentage basis, liver composition was otherwise unaffected by the continuous administration of GH. In summary, pulsatile administration of GH induced hepatomegaly, largely due to cell hypertrophy, with no change in relative tissue composition. The continuous administration of GH had no effect on liver size, tissue composition, or most nucleic-acid-based indicators of cell hypertrophy or hyperplasia. Thus, previously observed differences in overall growth performance due to pattern of GH administration were also reflected in selected target-tissue response.

Secretory pattern of growth hormone, insulin, and related metabolites in growing male turkeys: effects of overnight fasting and refeeding

The effect of an overnight fast on the secretory profile of growth hormone (GH), insulin, and related metabolites [glucose, nonesterified fatty acids (NEFA) and triglycerides (TG)] was determined in two separate experiments with 8- and 9-wk-old male turkeys. Toms were provided feed ad libitum or were fasted 20 h prior to sampling. Blood samples (.6 to .7 mL) were collected every 10 min for 8 h from the toms showing a positive weight gain between cannulation and the initiation of the experiment. Overall and baseline, GH levels were higher for the fasted birds versus the fed birds. The GH peaks for the fasted birds were of shorter duration than those for the fed birds, but were more frequent. The plasma NEFA levels of the fasted birds were higher than those of the fed birds. Plasma TG was lower for the fasted than the fed group. Insulin, which was secreted in a pulsatile fashion, was lower for the fasted versus the fed birds. Fasting produced no change in plasma glucose. A separate group of fasted males was refed after 4 h of sampling; the plasma levels of GH, insulin, and metabolites returned to those observed in birds given feed ad libitum within 30 min of refeeding. There appeared to be no relation between the pulsatile release of GH and the circulating levels of NEFA.

Pulsatile patterns of plasma growth hormone in turkeys: effects of growth rate, age, and sex

Male and female turkeys of a slow-growing, random bred line (RBC-2) and a fast-growing line (F), selected over 21 generations from RBC-2 for increased 16-week body weight, were intravenously cannulated and serially sampled at 10-min intervals for 6, 8, 9, 10, or 12 hr at 2, 4, 8, 14, and 24 weeks of age, respectively, for determination of the pulsatile pattern of plasma growth hormone (GH) concentration. Overall mean plasma GH concentration was greater for RBC-2 than F beginning at 4 weeks of age, when body weights of the two lines had diverged. Males exhibited both greater body weight and greater overall mean GH than females beginning at 4 weeks of age. Overall mean GH concentration, peak frequency and amplitude, and baseline concentrations declined with age for both lines. The RBC-2 line exhibited greater peak frequency, peak amplitude, and baseline mean concentration than the F line at 4, 8, and 14 weeks of age. Males exhibited greater peak frequency, peak amplitude, and baseline concentration than females at 4, 8, and 14 weeks of age. Peak duration was the most consistent profile parameter across lines, ages, and sexes, and averaged 68 min overall. Estimated GH pool size was consistently greater in males than females at all ages, and was greater in the F than RBC-2 line at 2 weeks of age when relative gain was maximal for both lines. Pool size was the GH parameter most highly correlated with body weight across treatment groups.

Effect of subcutaneous infusion of pituitary-derived chicken growth hormone on growth performance of broiler pullets

The effect of subcutaneous infusion of pituitary-derived chicken growth hormone (p-cGH) on plasma hormone/metabolite status and growth performance of young broiler pullets was investigated. Two-week-old pullets were surgically prepared and maintained via a fluid swivel/spring tether/harness system. Birds were subcutaneously infused 24 h a day for 21 days with 1.0 mL/day of either a p-cGH or vehicle (control) solution (20 micrograms/kg BW/day). Subcutaneous infusion of p-cGH had no significant effect on growth performance parameters in comparison with controls. Differences between levels of overall feed intake, net BW gain, feed efficiency, and carcass composition were not significant for treatments. However, dressing percentage was lower in p-cGH treated birds than in vehicle infused birds (P less than .04). Growth hormone treatment resulted in a modest degree of enlargement of the liver (P less than .06). However treatment had no effect upon wet weights of other measured organs or upon parameters of longitudinal bone growth, including length and mass of the tibiotarsus and width of the epiphyseal growth plate. Differences between treatment groups in preinfusion plasma concentration of GH, insulin, and glucose were not significant. Postinfusion plasma concentrations of GH were elevated over three-fold by p-cGH treatment (P less than .0001), with no treatment differences in plasma insulin or glucose concentrations. This study indicated that a sustained, 24-h elevation in plasma GH concentration in response to a physiological dosage of exogenous p-cGH is ineffective in altering growth performance of young, rapidly growing meat type chickens.

A method for catheterization, harnessing and chronic infusion of undisturbed chickens

A system was designed to facilitate the chronic infusion and/or serial blood sampling of rapidly growing, meat-type chickens with little or no stress to the bird. Techniques for surgically preparing an indwelling catheter, fabricating a harness system to protect this catheter, utilizing a miniature fluid swivel to provide free movement and infusing solutions via a programmable pump are described.

Effect of pattern of administration on the response to exogenous pituitary-derived chicken growth hormone by broiler-strain pullets

The effect of pulsatile versus continuous intravenous administration of exogenous, pituitary-derived chicken growth hormone (cGH) on growth performance and endocrine/metabolite status of broiler-strain pullets was determined. In a first study, 8-week-old pullets, surgically prepared with intravenous catheters and maintained via a fluid swivel/spring tether/harness system, were administered cGH or vehicle (control) over a 10-min period every 90 min (i.e., 90-min pulse pattern) for 21 consecutive days. Feed intake, body weight gain, and carcass yield and composition were determined in conjunction with plasma concentrations of several hormones and metabolites. In a second study, 8-week-old pullets were intravenously administered cGH or vehicle continuously for 21 consecutive days under the same conditions as for Study I. Pulsatile cGH administration improved feed efficiency (P less than 0.02), increased longitudinal bone growth (P less than 0.02) and mass (P less than 0.01), and reduced abdominal fat pad size (P less than 0.05) and total carcass lipid (P less than 0.09) over the 21-day treatment period in comparison to vehicle infusion. Pulsatile cGH administration also resulted in hepatomegaly, a marked elevation in plasma IGF-I (P less than 0.003) and T3 (P less than 0.005) concentrations, and a reduction in plasma T4 levels (P less than 0.04). In contrast to the above responses to pulsatile cGH, continuous intravenous cGH administration significantly impaired feed efficiency (P less than 0.01) and had no significant effect on abdominal fat pad or liver size or on total carcass lipid, but did result in widening of the epiphyseal growth plate (P less than 0.06) and increased bone mass (P less than 0.01) in comparison to vehicle infused controls. These studies demonstrate that in the broiler chicken, for which endogenous plasma GH concentrations are pulsatile at early ages in conjunction with rapid growth, the pattern of exogenous GH administration is clearly a factor influencing the nature of response to the hormone.

Relationship of plasma growth hormone to growth within and between turkey lines selected for differential growth rates

The ontogeny of plasma growth hormone (GH) was determined within and between genetically-related turkey lines selected for differential growth rates. Blood samples were obtained at weekly intervals from hatching through 195 days of age from male and female poults of a slow-growing, randombred line (RBC-2), representing the base population, and a fast-growing line selected over 20 generations from RBC-2 for increased 16-wk body weight (F). Growth rate of the F line exceeded that of RBC-2 during the very early (0 to 14 day) posthatch period (P less than .05), but was not different from that of the RBC-2 line by 77 to 195 days of age. Males of both lines were larger than females at all ages (P less than .05). Plasma GH increased from hatching until 2 wk of age and declined thereafter in both lines. Differences between overall plasma GH concentrations of the lines were not observed during the 0 to 14 day period, but concentrations were higher (P less than .05) in RBC-2 than F birds thereafter (21 to 195 days of age). Plasma GH concentrations initially (0 to 14 days) were higher in females than in males for both lines (P less than .05), but thereafter (21 to 195 days) declined more rapidly and averaged lower overall in females than in males (P less than .05). Correlations between measures of GH and growth rate within lines over age were strongly positive (r = .83 to .93; P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)